Australia markets closed

Genetic Technologies Limited (GTG.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.00700.0000 (0.00%)
At close: 2:41PM AEST
Full screen
Previous close0.0070
Open0.0070
Bid0.0070 x 10000000
Ask0.0080 x 249000000
Day's range0.0070 - 0.0070
52-week range0.0060 - 0.0140
Volume661,249
Avg. volume2,510,034
Market cap64.583M
Beta (5Y monthly)0.89
PE ratio (TTM)N/A
EPS (TTM)-0.0010
Earnings date30 Aug 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est0.25
  • PR Newswire

    BelHealth Completes Asset Sale of General Genetics Corp.

    September 9, 2021–BelHealth Investment Partners, LLC ("BelHealth") is pleased to announce that it has completed the sale of assets of the international division of General Genetics Corporation (GGC), a provider of relationship and clinical genetic testing services, to Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company ("GTG"). The transaction was structured in a combination of cash and stock of GTG.

  • GlobeNewswire

    Genetic Technologies Reports FY21 Results as it Turns the Corner on its Commercialization Strategy

    Company to present at H.C. Wainwright 23rd Annual Global Investment Conference taking place virtually September 13-15, 2021MELBOURNE, Australia, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in Genomics based tests in health, wellness and serious disease, is pleased to provide the financial results for the year ended June 30, 2021. Highlights Revenues from customers of A$120k including receipt of first month sales from

  • GlobeNewswire

    Genetic Technologies Enters Multi-Billion-Dollar Consumer Genomics Market

    EasyDNA Acquisition Accelerates Global Expansion PlansMELBOURNE, Australia, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in Genomics based tests in health, wellness and serious disease, is pleased to announce the completion of its acquisition of EasyDNA (‘the acquisition’) for US$4 million in cash and stock on August 13, 2021. Overview BelHealth becomes a shareholder of Genetic Technologies with 2.3% holding following